Leading Growth Driver in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market in 2025: Rising Diabetes Prevalence Fuels Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Driver's Influence

Which drivers are expected to have the greatest impact on the over the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market's growth?
The rise in diabetes cases worldwide is projected to spur the expansion of the market for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics. Diabetes, a long-term metabolic condition, is marked by persistently high blood sugar levels, or hyperglycemia, resulting from the body's inability to generate sufficient insulin or efficiently use the insulin it does produce. PERT or pancreatic enzyme replacement therapy, an EPI treatment, can aid in better absorption of nutrients in diabetes patients with EPI and can also enhance glycemic control. For example, The National Health Service (NHS England) reported in June 2024, that in England, the count of individuals with pre-diabetes identified by NHS in 2023 spiked to 3,615,330, showing an 18% rise from 3,065,825 in 2022. Moreover, the number of cases for people under 40 jumped by almost 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Thus, the escalating diabetes demographic is catalyzing the expansion of the EPI therapeutics and diagnostics market. The surging cases of gastrointestinal diseases are predicted to bring about forward-moving growth in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Gastrointestinal diseases encompass various medical conditions that affect the parts of the body involved in digestion. The role of EPI therapeutics and diagnostics is critical in the management of such diseases as they help address the deficiency of essential enzymes and support the process of digestion. For instance, Crohn's and Colitis Canada, a non-profit organization in Canada, reported in June 2023, that over 322,600 Canadians were projected to have inflammatory bowel diseases (IBD) in 2023, which is approximately 0.82% of the population. As IBD prevalence grows, it is projected that by 2035, around 470,000 Canadians-roughly 1.1% of the population or 1 in 91 people-will be living with IBD. Therefore, the climbing frequency of gastrointestinal diseases is expected to steer upward growth in the market for EPI therapeutics and diagnostics.

Get Your Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What is the future CAGR of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and how will it impact industry expansion?
In recent times, there has been a significant expansion in the market size of exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics. The market value is set to increase from $5.69 billion in 2024 to $6.17 billion in 2025, reflecting an 8.4% compound annual growth rate (CAGR). The historical growth in this market has been fueled by factors such as an uptick in the prevalence of underlying health conditions, progress in diagnostic technologies, advancements in pharmaceuticals, and broader global access to healthcare services.

The market size for therapeutics and diagnostics related to exocrine pancreatic insufficiency (EPI) is predicted to witness substantial growth in the coming years, expanding to $8.32 billion by 2029 with a compound annual growth rate (CAGR) of 7.8%. This predicted growth over the forecast period is associated with factors such as the advent of telemedicine and remote patient monitoring, the implementation of data analytics and AI, patient education and support, as well as regulatory alterations and reimbursement policies. The forecast period is also expected to see major trends such as personalized treatment strategies, the advancement of new therapies, less intrusive diagnostic procedures, and cooperative care models.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What are the emerging trends shaping the future of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
Prominent firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are embracing a strategic partnership model to boost technological integration and broaden their market scope. A strategic partnership generally denotes a mutual relationship between two or more entities in which they pool their resources, skills, and initiatives to attain shared aims or targets. For example, in February 2023, Codexis, Inc., an American protein engineering corporation, and Nestlé Health Science, a Switzerland-based nutrition science company, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, a potential therapy directed towards treating exocrine pancreatic insufficiency (EPI). The findings from this initial trial set the stage for subsequent investigations that have the potential to significantly enhance the treatment alternatives for EPI patients.

Which key market segments comprise the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market and drive its revenue growth?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented -

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992

What regions are at the forefront of exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market expansion?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the leading players fueling growth in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Is Covered In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report?

• Market Size Forecast: Examine the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market for a structured understanding.
• Key Players Overview: Analyze major players in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market.
• Segment Contributions: Evaluate how different segments drive overall growth in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market.
• Industry Challenges: Identify potential risks and obstacles affecting the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market.
• Competitive Landscape: Review strategic developments in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.